Ron Eastman has over 35 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, where he spent 15 years managing pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, Ron has helped build three private healthcare companies—Geron, HCORP, and Rinat Neuroscience.
Under his leadership, Geron became a cutting-edge biotech company which grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. At Rinat, a private biotech company spun out of Genentech with the support of Essex Woodlands in late 2001, Ron led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006.
Ron serves on the boards of Corium International, EluSys Therapeutics, Inc., IntegenX Inc., Revance Therapeutics, Inc., Suneva and Symphogen.
Ron joined Essex Woodlands in the Palo Alto office in October 2006 and is a Managing Director.
Ron holds a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. In his spare time, Ron enjoys swimming, biking, running and the occasional triathlon.